Immunocore Holdings PLC ADR IMCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMCR is a good fit for your portfolio.
News
-
Immunocore announces upcoming presentation and posters at ASCO 2024
-
Immunocore to present at upcoming investor conferences
-
Immunocore presented two posters at CROI 2024
-
Immunocore to present at upcoming investor conferences
-
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
-
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
-
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
-
Immunocore Prices Upsized Convertible Senior Notes Offering
Trading Information
- Previous Close Price
- $58.00
- Day Range
- $56.10–58.94
- 52-Week Range
- $42.21–76.98
- Bid/Ask
- $58.36 / $92.70
- Market Cap
- $2.92 Bil
- Volume/Avg
- 403,551 / 414,950
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 497
- Website
- https://www.immunocore.com
Valuation
|
Metric
|
IMCR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.19 |
Price/Sales | 9.22 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMCR
|
|---|---|
Quick Ratio | 3.63 |
Current Ratio | 3.80 |
Interest Coverage | −14.30 |
Quick Ratio
IMCR
Profitability
|
Metric
|
IMCR
|
|---|---|
Return on Assets (Normalized) | −2.69% |
Return on Equity (Normalized) | −5.23% |
Return on Invested Capital (Normalized) | −6.48% |
Return on Assets
IMCR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yhpjhhdrh | Hcdd | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nkzjzjws | Jlcsvy | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ktqzmnm | Yzjqb | $97.8 Bil | |
MRNA
| Moderna Inc | Mkhgfyk | Wqz | $41.3 Bil | |
ARGX
| argenx SE ADR | Jcvhbryd | Ktk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dxwhbbqf | Xnsr | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jlxsflhyx | Crvmgnh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yqmyzvgts | Mvcxbt | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rdbydhsyrs | Ztnhdx | $12.5 Bil | |
INCY
| Incyte Corp | Dldpvls | Bsqrvp | $11.6 Bil |